Phase II Trial of Nu-V3 Non-Invasive Nerve Stimulation Device for Chronic Pain, Anxiety, Depression, Sleeplessness
Paused · Not applicable
Conditions studied: Chronic Pain, Anxiety, Depression, Sleeplessness
In brief
This Nu-V3 clinical study is a randomized, phase II, open-label study evaluating the Nu-V3 cranial nerve stimulation treatment device in patients with chronic pain, anxiety, depression, and/or sleeplessness.
Key facts
- Study ID
- NCT05394545
- Run by
- Nu-Life Solutions
- People needed
- 80
- Starts
- 2024-03-20
- Expected to finish
- 2025-05-31
- Last updated by the study team
- 2023-07-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Participant is at least 18 years of age
- Participant presents with one or more of the following symptoms: chronic pain, anxiety, depression, and/or sleeplessness
- Participants must score greater than or equal to a 5/10 for their primary symptom score on the Baseline Symptom Questionnaire
- Patient's chosen primary symptom must have an available accrual slot for the participant. If patient scores greater than or equal to a 5/10 for a second symptom, they can be selected to accrue to another symptom slot.
- Participant has signed the Informed Consent Form
You may not qualify if…
- Participants with a hearing aid
- Participants with a pacemaker
- Participants with irregular heart rate or a heart rate lower than 60 beats per minute (bradycardia)
- Have had a transplant within the last 2 years
- Have had a heart attack or cardiac bypass surgery within the last 12 months
- Patients with complaints of dizziness or lightheadedness within the last 3 months
- Women who are pregnant
- Participants with Diabetic Retinopathy
- Current ear infection
- SBP < 100 and/or DBP < 60
- History of uncontrolled bipolar disorder within the last 12 months
- History of uncontrolled seizures within the last 12 months
- History of aneurysms
- History of syncope within the last 12 months
- Participants that have had a TIA or stroke within the last 12 months
- Participants with health problems deemed at risk for the study by the Principal Investigator
- Participants with any changes to Pain/Anxiety/Depression/Sleeplessness medications within last 60 days (participants that do not meet this medication- change washout period may be delayed until 60-day period is met)
- Participants that are currently under adjudication process for disability support, VA or other
Where it is running
- Greater Chicago Specialty Physicians (GCSP) - Schamuburg — Schaumburg, Illinois, United States
- EZ Clinic — Greenwood, Indiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.